No Data
No Data
Proya CosmeticsLtd (SHSE:603605) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it
Swhy: The penetration rate continues to increase coupled with the rise of domestic products, bullish on the cosmetic and medical beauty sector.
The medical beauty industry will continue to benefit from a rich supply of products and maintain healthy development through industry standardization.
Proya Cosmetics Likely to Post Strong Sales Growth in 2Q -- Market Talk
0526 GMT - Proya Cosmetics is likely to post strong sales growth in 2Q, following its good performance at the recent 618 online shopping festival, CGS International analysts say in a note. "We believe
Proya Cosmetics Target Price Raised to CNY178.0 From CNY172.0 by CGS International >603605.SH
Proya Cosmetics Target Price Raised to CNY178.0 From CNY172.0 by CGS International >603605.SH
Consumer blue chips, which account for 20% of foreign investment.
Can it still resist the fall?
Citi: Hugebio will be the primary beneficiary of the structural trend of "medicalization of skincare", first giving a "buy" rating.
Citigroup released a research report that first gave Proya Cosmetics (02367) a "buy" rating, stating that it will be the main beneficiary of the structural trend of "skin care medicalization". It is expected that net income will increase by 35% in the first half of 2024, and the compound annual growth rate from 2023 to 2026 will reach 26%. The report pointed out that although the overall demand for cosmetics has slowed down, skin beauty and care products are expected to continue to flourish due to the growing demand of young consumers. The China's cosmetic companies that the bank is bullish on are Proya Cosmetics (603605. SH), Juzi Biotechnology, and Betaine (300975.SZ) in order.
No Data